BME100 f2013:W1200 Group18 L1
|BME 100 Fall 2013|| Home |
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help
LAB 1 WRITE-UP
Independent and Dependent Variables
There are 21 groups ranging from no dose to 9.5 mg. Each group has different intervals of the doseages of the inflammatory inducing drug. The test dosage groups are as follows: 0, .5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, and 9.5 (all measured in milligrams).
Sources of Error and Bias
(Potential Errors) One potential source of error are test subjects with pre-existing conditions. Pre-existing conditions can be further complicated when given Lipopolysaccharide and can contribute to changes in Inflammotin levels. Dug allergies can also affect Inflammotin levels. To eliminate these risks, a medical examination testing for pre-existing conditions and drug allergies should be preformed before beginning the drug trial and those that test positive for either should be excluded from the drug trial. Another potential source of error to consider are the different initial levels of Inflammotin in each test subject. Without knowing these values, we can not measure change after the drug has been administered. To solve this, an ELISA test should be preformed on samples of blood from each test subject and initial Inflammotin levels should be recorded. Lastly, Lipopolysaccharide may have limited effects on some patients. By monitoring the test subjects for a period of three months, we will be able to monitor the short and long-term effects on Inflammotin levels.